Patents Assigned to Hoescht Aktiengesellschaft
  • Patent number: 6348312
    Abstract: The invention relates to novel stabilized oligonucleotides in which at least one non-terminal pyrimidine nucleoside is modified, and to their use as a diagnostic or pharamaceutical for the treatment of viral infections, cancer or diseases in which integrins or cell-cell adhesion receptors are active.
    Type: Grant
    Filed: November 10, 1994
    Date of Patent: February 19, 2002
    Assignee: Hoescht Aktiengesellschaft
    Inventors: Anuschirwan Peyman, Eugen Uhlmann, Matthias Mag, Gerhard Kretzschmar, Matthias Helsberg, Irvin Winkler
  • Patent number: 6004938
    Abstract: The invention relates to inositolglycans having insulin-like action. Specific compounds are provided having the formula IA--Z--R (I)where A is the radical H--P(O)(OH)--, H--P(S)(OH)--, HO--P(S)(OH)--, HS--P(S)(OH)--, (C.sub.1 -C.sub.4)-alkyl-P(O)(OH)--, (C.sub.1 -C.sub.4)-alkyl-P(S)(OH)--, S(O).sub.2 (OR.sup.1)--, S(O)(OR.sup.1)--, NH.sub.2 --C(O)--, R.sup.1 R.sup.2 N--, R.sup.1 R.sup.2 N--C(O)--NH--, R.sup.1 O--SO.sub.2 --NH--, (C.sub.1 -C.sub.4)-alkyl-SO.sub.2 --, (C.sub.1 -C.sub.4)-alkyl-S(O)-- or R.sup.1 --S--, Z is 2 to 6 substituted or unsubstituted sugar radicals and R is substituted or unsubstituted inositol. The inventive compounds are suitable for the treatment of diabetes mellitus or noninsulin-dependent diabetes.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: December 21, 1999
    Assignee: Hoescht Aktiengesellschaft
    Inventors: Wendelin Frick, Guenter Mueller
  • Patent number: 5976811
    Abstract: Antibodies for the selective immunological determination of bile acids in biological matricesPolyclonal antibodies for the selective immunological determination of bile acids in biological matrices, a process for the preparation of these antibodies, and their use in immunoassays are described.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: November 2, 1999
    Assignee: Hoescht Aktiengesellschaft
    Inventors: Stefan Mullner, Axel Hoffmann
  • Patent number: 4959351
    Abstract: The invention relates to a process for the preparation of crystal suspensions of one or more insulin derivatives of the formula I ##STR1## R.sup.1 denotes H or H-Phe, R.sup.30 represents the radical of a neutral L-aminoacid which can be genetically coded andR.sup.31 represents a physiologically acceptable organic group of basic character with up to 50 carbon atoms, in the build-up of which 0 to 3 .alpha.-aminoacids participate and in which any terminal carboxyl function present can be free, as the ester function, as the amide function, as the lactone or reduced to CH.sub.2 OH, with an isoelectric point between 5.8 and 8.5,which comprises carrying out the crystallization in an aqueous medium close to the isoelectric point of the derivative or derivatives in the presence of an aromatic hydroxy compound, to crystals and crystal suspensions obtained by the process and to the use thereof.
    Type: Grant
    Filed: July 27, 1984
    Date of Patent: September 25, 1990
    Assignee: Hoescht Aktiengesellschaft
    Inventor: Ulrich Grau